Introduction:
The biologics industry in Britain continues to thrive in 2026, with an increasing focus on innovation and market growth. With advancements in technology and research, the top 30 premier biologic companies in Britain are leading the way in producing high-quality biologic products. The industry has seen a steady increase in production volume, with exports reaching new heights in recent years.
Top 30 Premier Biologic Companies in Britain 2026:
1. GlaxoSmithKline (GSK)
– Market share: 15%
– GSK remains a powerhouse in the biologics industry, with a strong focus on research and development.
2. AstraZeneca
– Market share: 10%
– AstraZeneca continues to be a key player in the biologics market, with a diverse portfolio of products.
3. Roche
– Market share: 8%
– Roche’s biologics division continues to see growth, with a focus on oncology and autoimmune diseases.
4. Novartis
– Market share: 7%
– Novartis has made significant investments in biologics, particularly in the area of biosimilars.
5. Pfizer
– Market share: 6%
– Pfizer’s biologics portfolio continues to expand, with a strong presence in the global market.
6. Johnson & Johnson
– Market share: 5%
– Johnson & Johnson’s biologics division is known for its innovative products and cutting-edge research.
7. Merck
– Market share: 4%
– Merck has a strong focus on biologics, particularly in the area of vaccines and cancer treatments.
8. AbbVie
– Market share: 3%
– AbbVie’s biologics division has seen steady growth, with a focus on immunology and oncology.
9. Biogen
– Market share: 3%
– Biogen is a key player in the biologics industry, with a focus on neurology and rare diseases.
10. Amgen
– Market share: 2%
– Amgen continues to be a leader in the biologics market, with a strong focus on biotechnology.
Insights:
The biologics industry in Britain is set to continue its growth trajectory in the coming years, with a focus on innovation and research. With an increasing demand for biologic products globally, the top 30 premier biologic companies in Britain are well-positioned to capitalize on this trend. Investments in technology and research will be key drivers of growth, with a focus on developing new and improved biologic products. As the industry continues to evolve, collaboration and partnerships will play a crucial role in driving innovation and market expansion.
Related Analysis: View Previous Industry Report
